Zai Lab Limited has announced plans for a pivotal clinical trial of ZL-1310, a Delta-like ligand 3 (DLL3) antibody-drug conjugate $(ADC)$, aimed at treating patients with extensive-stage small cell lung cancer (ES-SCLC). The company intends to begin the randomized registrational study later this year, comparing the selected dose of ZL-1310 against the current standard of care for second-line treatment. This follows updated data from an ongoing global Phase 1a/1b trial, which demonstrated a favorable safety profile and promising efficacy. Additionally, Zai Lab is actively enrolling patients in a front-line SCLC study and in other neuroendocrine carcinomas, with further data updates anticipated in the coming months. An investor conference call and webcast to discuss these developments is scheduled for June 2, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.